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Abstract
Background: Sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables, is a common dietary component that
has histone deacetylase inhibition activity and exciting potential in cancer prevention. The mechanisms by which SFN
imparts its chemopreventive properties are of considerable interest and little is known of its preventive potential for breast
cancer.
Principal Findings: We found that SFN significantly inhibits the viability and proliferation of breast cancer cells in vitro while
it has negligible effects on normal breast cells. Inhibition of telomerase has received considerable attention because of its
high expression in cancer cells and extremely low level of expression in normal cells. SFN treatment dose- and time-
dependently inhibited human telomerase reverse transcriptase (hTERT), the catalytic regulatory subunit of telomerase, in
both MCF-7 and MDA-MB-231 human breast cancer cells. DNA methyltransferases (DNMTs), especially DNMT1 and DNMT3a,
were also decreased in SFN-treated breast cancer cells suggesting that SFN may repress hTERT by impacting epigenetic
pathways. Down-regulation of DNMTs in response to SFN induced site-specific CpG demethylation occurring primarily in
the first exon of the hTERT gene thereby facilitating CTCF binding associated with hTERT repression. Chromatin
immunoprecipitation (ChIP) analysis of the hTERT promoter revealed that SFN increased the level of active chromatin
markers acetyl-H3, acetyl-H3K9 and acetyl-H4, whereas the trimethyl-H3K9 and trimethyl-H3K27 inactive chromatin markers
were decreased in a dose-dependent manner. SFN-induced hyperacetylation facilitated the binding of many hTERT
repressor proteins such as MAD1 and CTCF to the hTERT regulatory region. Depletion of CTCF using siRNA reduced the SFN-
induced down-regulation of hTERT mRNA transcription in these breast cancer cells. In addition, down-regulation of hTERT
expression facilitated the induction of cellular apoptosis in human breast cancer cells.
Significance: Collectively, our results provide novel insights into SFN-mediated epigenetic down-regulation of telomerase in
breast cancer prevention and may open new avenues for approaches to SFN-mediated cancer prevention.
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Introduction
Epidemiological studies have consistently shown that an
increased dietary intake of fruits and vegetables is strongly
associated with reduced risk of developing chronic diseases, such
as cardiovascular disease, diabetes, and cancer [1–2]. Sulforaph-
ane (SFN), an isothiocyanate naturally rich in widely consumed
cruciferous vegetables such as broccoli, broccoli sprouts, cabbage
and kale, has been shown to reduce the risk of developing many
common cancers, including breast cancer [3–7]. SFN was first
identified as a potent inducer of phase 2 detoxification enzymes
[8], and studies have also found other anti-carcinogenic as well as
anti-oxidant mechanisms including induction of caspases, induc-
tion of glutathione S-transferase, inhibition of cytochrome P450
isoenzymes and reduction of the DNA binding ability of nuclear
factor-kB [6–8]. However, there has been growing interest in
epigenetic regulation by SFN in chemoprevention due to its
histone deacetylase (HDAC) inhibition activity [9–12]. The
HDAC inhibition activity of SFN has been shown to lead to an
increase in the global and local histone acetylation status of a
number of genes [9,13–14]. SFN-mediated epigenetic alterations
are believed to be strongly involved in the process of cancer
chemoprevention by altering the expression of various genes,
including tumor suppressor genes in various cancers [5].
The human telomerase reverse transcriptase (hTERT) gene that
encodes the catalytic subunit of telomerase is a highly epigenet-
ically-regulated gene, and is widely expressed in more than 90% of
human cancers but not in normal somatic cells. hTERT is a
promising target for cancer therapeutics and an important marker
for the diagnosis of malignancy [15–16]. This critical gene is
regulated by several epigenetic alterations at promoter sites
including histone acetylation and promoter methylation [15–17].
Histone acetylation and deacetylation are dynamic processes
typically regulated by histone acetyltransferases (HATs) and
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complexes to transfer acetyl groups to lysine residues in histones.
This leads to an open chromatin structure which facilitates the
binding of various transcription factors such as c-MYC, MAD1
and CTCF to gene promoters for the activation or repression of
genes, including hTERT [17–19]. In addition to histone acetyla-
tion as a form of epigenetic control of hTERT expression,
promoter DNA methylation and histone methylation also play
significant roles in hTERT regulation [19–20]. Convincingly, the
hTERT promoter region is embedded in a CpG island (positions
21100 to +1500), and this region is mostly hypermethylated by
specific DNA methyltransferases (DNMTs) in cancer cells except a
short region in the hTERT core promoter (positions 2279 to +5)
[21]. The aberrant methylation pattern in the hTERT 59-
regulatory region prevents the binding of the methylation-sensitive
CTCF repressor to the first exon of hTERT [22]. hTERT
regulatory region hypermethylation has been associated with
increased hTERT expression, whereas demethylation of this region
inhibits hTERT transcription [21–22]. This phenomenon is
opposite to the general model of gene activation, in which the
presence of methylated cytosines in a promoter typically inhibits
gene transcription.
In addition to histone acetylation and promoter methylation,
histone methylation- mediated transcriptional regulation of
hTERT expression has emerged. Histone acetylation-mediated
transcriptional binding of MAD1 recruits RBP2 (a histone
demethylase) to the hTERT promoter and reduced hTERT mRNA
expression is accompanied by H3 lysine-4 demethylation [23].
Studies have shown that the HDAC inhibitor, trichostatin A
(TSA), induces hyperacetylation of histones at the hTERT
proximal promoter and directly transactivates the hTERT gene
in normal human-telomerase negative cells [24–25]. In contrast,
many studies have also shown that HDAC inhibitors suppress
hTERT expression in various cancer cells including prostate,
leukemic and oral squamous cell carcinoma [18,26–27]. Reports
on telomerase inhibition by HDAC inhibitors are controversial,
however, most studies have focused on down-stream mechanisms
of hTERT inhibition such as apoptosis and cell cycle arrest rather
than how the HDAC inhibitors regulate hTERT expression.
Therefore the present study was undertaken to evaluate the
complete epigenetic regulation of hTERT expression and its
promoter alterations in the apoptosis process induced by SFN in
human breast cancer cells. Our results indicate that SFN-induced
histone acetylation allows transcriptional repressors to bind to the
hTERT 59-regulatory region. Further, SFN-mediated demethyla-
tion of CpG sites in the exon 1 region of the hTERT gene via
down-regulation of DNMTs and induction of RBP2, allows the
CTCF repressor of hTERT to bind to exon 1 of the hTERT gene
thereby contributing to the inhibition of hTERT expression. These
findings reveal for the first time that SFN alters the methylation
status of the hTERT regulatory region at CpG sites on exon 1 but
not in the promoter region. Collectively, our studies indicate that
changes in the histone modifications of the hTERT promoter and
DNA demethylation of hTERT exon 1 lead to inhibition of cellular
growth and the induction of apoptosis of human breast cancer cells
in response to the SFN chemoprevention compound.
Materials and Methods
Cell culture and cell growth assay
All human cell lines were obtained from the American Type
Culture Collection (ATCC, Manassas, VA). Breast cancer MCF-7
and MDA-MB-231 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) (Mediatech Inc, Manassas, VA)
supplemented with 10% fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA) and 1% penicillin/streptomycin (Mediatech).
Normal control MCF10A cells were obtained from ATCC and
maintained in DMEM/F-12 medium (Mediatech) supplemented
with 5% equine serum (Atlanta Biologicals), 10 mg/ml of human
insulin (Sigma, St. Louis, MO), 20 ng/ml of epidermal growth
factor (Sigma), 100 ng/ml of cholera endotoxin (Sigma), 0.5 mg/
ml of hydrocortisone (Sigma), 2 mM L-glutamine and 1%
penicillin/streptomycin (Mediatech). MCF10A is a non-tumori-
genic human breast epithelial cell line originally isolated from a
36-year-old Caucasian female. It has been frequently used as a
normal human breast cell control [28–30]. R,S-sulforaphane
(LKT Laboratories, Minneapolis, MN) was prepared in DMSO
and stored at a stock concentration of 10 mmol/L at 220uC.
Twenty-four hours after seeding the cells, SFN was added to the
culture medium at indicated concentrations and the maximum
concentration of DMSO was 0.1% (v/v) in the medium. Cells
treated only with DMSO served as a vehicle control. For cell
growth assay, total viable cell numbers were calculated using a
hemocytometer and plotted against number of treatment days.
Cells were washed and treated with fresh SFN every three days of
culture.
Colonogenic assay
Approximately 500 cells were seeded into six-well plates in
triplicate for each group and allowed to adhere overnight.
Thereafter, cell culture medium was changed and cells were
treated with 0, 5, 10, 15 and 20 mmol/L SFN. The cells were
allowed to incubate at 37uC in the incubator undisturbed for 15
days. During this period each individual surviving cell would
proliferate and form colonies. On day 15, the colonies were
washed with cold phosphate buffer saline, fixed with cold 70%
ethanol and stained with 0.25% trypan blue solution. The colonies
that had $50 cells/colony were counted and expressed as percent
control.
Total RNA extraction, RT-PCR, and real-time quantitative
PCR
Total cellular RNA was isolated from cultured cells using an
RNeasy mini kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. Two micrograms of total RNA was
reverse-transcribed into cDNA using the iScript cDNA synthesis
kit (Bio-rad, Hercules, CA). The PCR primer sets were follows:
sense59-CGG AAG AGT GTC TGG AGC AA-39 and anti-sense
59-GGA TGA AGC GGA GTC TGG A-39,a tT m5 2 uC for
hTERT;5 9-TTA CAC GTG TCC ACG GCG TTC-39 and anti-
sense 59-GCT TGT ATG TGT CCC TGC TGG CA-39,a tT m
59uC for CTCF; sense 59-ACC ACA GTC CAT GCC ATC AC-
39 and anti-sense 59- TCC ACC CTG TTG CTG TA-39,a tT m
54uC for GAPDH. The reaction conditions were 35 cycles of 94uC
for 30 sec, TmuC for 30 sec and 72uC for 25 sec. GAPDH was
used as an internal loading control. Real-time quantitative PCR
was carried out in a Bio-Rad MyiQ thermocycler (Bio-rad,
Hercules, CA) using Platinum SYBR Green detection system
(Invitrogen, Carlsbad, CA). The primer sets were follows: sense 59-
AGG GGC AAG TCC TAC GTC CAG T-39 and anti-sense 59-
CAC CAA CAA GAA ATC ATC CAC C-39 for hTERT, and
sense59- GAA GGT CGG AGT CAA CGG ATT T-39 and anti-
sense 59- ATG GGT GGA ATC ATA TTG GAA C-39 for
GAPDH. Both primers have a Tm of 60uC. The calculations for
determining the relative level of gene expression were made using
the cycle threshold (Ct) method. The mean Ct values from
duplicate measurements were used to calculate the expression of
the target gene using the formula: fold change in gene expression,
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2DDCt=2
2{DCt (SFN-treated samples)- DCt (untreated control)}, where
DCt=C t (hTERT)- Ct (GAPDH).
Telomerase activity assay
Telomerase activity was measured using TeloTAGGG telome-
rase PCR ELISA kit (Roche applied science, Indianapolis, IN)
according to the manufacturer’s protocol. Three micrograms of
protein from total cell lysates was added to the reaction mixture,
and the generated telomere product was PCR amplified using 30
cycles (25uC for 20 min, 94uC for 5 min, 94uC for 30 sec, 50uC
for 30 sec, 72uC for 90 sec and 72uC for 10 min). PCR amplified
products (5 mL) were used for ELISA assays, and the level of
telomerase activity was expressed as an arbitrary unit of
absorbance at OD450–OD690.
Western blot analysis
Protein was extracted from cultured cells using the RIPA lysis
buffer (Upstate Biotechnology, Lake Placid, NY) following the
manufacturer’s directions. Equal amounts of protein were
resolved on a 10% SDS-polyacrylamide gel and transferred onto
nitrocellulose membranes. After incubation in blocking buffer for
1 h, the membranes were incubated with the primary antibodies
specific for DNMT1, DNMT3a, DNMT3b, CTCF, RBP2 (Santa
Cruz Biotechnology, Santa Cruz, CA) and b-actin (Cell
Signaling, Danvers, MA). The blot was then washed with Tris-
Buffered Saline (TBS) with 0.05% (v/v) Tween-20 and incubated
with specific secondary antibody conjugated with horseradish
peroxidase. Protein bands were then visualized using the ECL
detection system (Santa Cruz Biotechnology) following the
protocol of the manufacturer. The bands were analyzed by using
Kodak 1D 3.6.1 image software for the intensity and normalized
with respective b-actin. The mean values for the control group
(nontreated) were assigned the value 1 (arbitrary unit), and
comparison was then made with densitometry values of other
SFN treatment groups.
HDAC activity assay
Nuclear extract (20 mg) from the SFN-treated as well as
untreated cells were assayed for HDAC activity using a
colorimetric HDAC assay kit (Active Motif, Carlsbad, CA)
according to the manufacturer’s instruction. Once the acetylated
substrate, BOC-(Ac)Lys-pNi-troanilide, is deacetylated, a colored
product results that absorbs maximally at 405 nm. No enzyme
control and TSA-positive controls were included and all reactions
were setup in triplicate.
HAT activity assay
HAT activity was determined using the colorimetric HAT
activity assay kit (Epigentek, Brooklyn, NY) according to the
manufacturer’s protocol. Nuclear extract from the SFN-treated as
well as untreated cells were assayed for HAT activity. The reaction
was initiated by adding 20 mg of nuclear extracts, containing active
HATs, to the active-histone coated ELISA plate and incubated for
60 min at 37uC. Acetylated histones were captured by specific
antibodies and followed by detection antibodies tagged with color
compound. The enzymatic color development was directly
proportional to HAT activity measured at 450 nm.
DNMT activity assay
Nuclear extract from the SFN-treated as well as untreated cells
were assayed for DNMT activity using a colorimetric DNMT
activity assay kit (Epigentek, Brooklyn, NY) according to the
manufacturer’s instruction. The reaction was initiated by adding
20 mg of nuclear extracts, containing active DNMTs, to the
unique cytosine-rich DNA substrate coated ELISA plate and
incubated for 60 min at 37uC. The methylated DNA can be
recognized with anti-5-methylcytosine antibody. The amount of
methylated DNA, which is proportional to enzyme activity, is
calorimetrically quantified at 450 nm.
Bisulfite sequencing analysis
To assess the methylation status of the hTERT promoter,
sodium bisulfite methylation sequencing was performed as
described previously [31]. Approximately 1 mg of genomic
DNA was used for bisulfite modification using the EpiTect-
Bisulfite modification kit following the manufacture’s protocol
(Qiagen, Valencia, CA). Modified DNAs were then amplified by
PCR using Go Taq mix (Promega, Madison, WI). Primers and
PCR-conditions were followed as described by Choi et al [19].
Following PCR amplification, purified bands were cloned using a
pGEM-T cloning kit (Promega). Plasmid DNA was isolated using
QIAprep Spin Miniprep kit (Qiagen). Plasmid DNAs were
sequenced using the 3730 DNA Sequencer (Applied Biosystems,
Foster City, CA).
Chromatin immunoprecipitation analysis
Chromatin immunprecipitation (ChIP) analysis was performed
using the EZ-ChIP kit (Cat#17-371; Lot# DAM1556786; Upstate
Biotechnology) according to the manufacturer’s instructions. The
antibodies used in the ChIP assays were ChIP-validated acetyl-
histone H3 (Cat#06-599; Lot#DAM1422332; Upstate Biotech-
nology), acetyl-histone H3K9 (Cat#07-352; Lot#DAM1394804;
Upstate Biotechnology), acetyl-histone H4 (Cat#06-598; Lot#
31991;Upstate Biotechnology), trimethyl-histone H3K27 (Cat#07-
449; Lot#DAM1421462; Upstate Biotechnology), trimethyl-his-
tone-H3K9 (Cat#07-442; Lot#DAM1411287; Upstate Biotech-
nology), MAD1 (Cat#05-1500; Lot#NG1578247; Upstate Bio-
technology), c-MYC (Cat#06-340; Lot#22590; Upstate
Biotechnology), HDAC1 (Cat#SC-8410; Lot#D2706; Santa Cruz
Biotechnology) and CTCF (Cat#SC-28198; Lot#A2508; Santa
Cruz Biotechnology). No antibody control was also used to check
ChIP efficiency. ChIP-purified DNA was quantified by using
quantitative-PCR (qPCR) on using Platinum SYBR Green
detection system (Invitrogen, Carlsbad, CA) as described by
Anderson et al [32]. Briefly, extracted DNA from each immuno-
precipitation was resuspended in 10 mL nuclease free water. In
parallel, the input DNA stored as 10% of total lysate was
resuspended in 100 mL nuclease free water. Real-time PCR was
performed in 25 mL volumes by using Platinum SYBR Green
detection system (Invitrogen). The primers for the hTERT
promoters were forward-59-TCC CCT TCA CGT CCG GCA
TT-39, reverse-59-AGC GGA GAG AGG TCG AAT CG-39.
Small interfering RNA (siRNA) knock-down of CTCF
Approximately 3610
5 cells per well was placed in a 6-well plate
and allowed to incubate overnight. The CTCF siRNA (Santa
Cruz Biotechnology) was made into 10 mM stock using nuclease
free water and 9 nM siRNA was delivered to the cells using the
Silencer siRNA Transfection kit (Ambion/Applied Biosystems,
TX, USA) according to the manufacturer’s instructions. siCON-
TROL Non-Targeting siRNA (Santa Cruz Biotechnology) was
used as a negative control. Cells were harvested and checked for
CTCF knock-down after 3 and 6 day intervals using western blot
analysis. SFN-treated and non-treated cells were used to harvest
RNA for PCR reactions using total RNA extraction and RT-PCR
procedures described in previous sections.
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Breast cancer cells transfected with CTCF and control siRNA
as well non-transfected cells were treated with 10 mM SFN for 6
days. The cells were then lysed with nuclei lysis buffer provided for
apoptosis assays using the Cell Death Detection ELISA Kit
(Roche, Palo Alto, CA) as described previously [33]. Briefly, the
cytoplasmic histone/DNA fragments were extracted from SFN-
treated and untreated cells and incubated in microtiter plate
modules coated with antihistone antibody. Subsequently, the
peroxidase-conjugated anti-DNA antibody was used for the
detection of immobilized histone/DNA fragments, followed by
color development with 2,29-azinobis(3-ethylbenzo-thiazoline-6-
sulfonic acid) substrate for peroxidase. The spectrophotometric
absorbance of the samples was recorded using Microplate Reader
(Bio-Rad Model 680, Hercules, CA) at 405 nm. Percent apoptosis
was calculated using the formula: (1006treatment cell absor-
bance/control cell absorbance)2100.
Statistical analysis
The statistical significance of differences between the values of
SFN-treated and non-SFN- treated controls was determined by
using Kruskal-Wallis with Dunn’s post test using GraphPad Prism
version 4.00 for Windows, GraphPad Software, San Diego,
California, USA, www.graphpad.com. In each case, P,0.05 was
considered statistically significant.
Results
SFN inhibits proliferation of human breast cancer cells at
concentrations that have negligible effects on normal
control breast cell
To determine the effective dose of SFN on breast cancer cells, we
first performed cell growth, morphological analysis and colonogenic
assays to detect cell proliferation status. As shown in Fig. 1, human
breast cancer MCF-7 (left panel) and MDA-MB-231 (middle panel)
cells as well as normal control human breast MCF10A (right panel)
cells were treated with the indicated concentrations of SFN for 3, 6
and 9 days for cell growth kinetics (Fig 1A) and colonogenic assays
(Fig 1C). We observed a dose- and time-dependent cell growth
inhibition with SFN treatment both in MCF-7 and MDA-MB-231
cells (Fig 1A). Doses of SFN up to 10 mM had negligible effects on
cell growth and proliferation of the control MCF10A cells while
these same doses inhibited these parameters for MCF-7 and MDA-
MB-231 cells. In addition, cell growth was completely inhibited at
15 mM and 20 mM of SFN after 6 days of treatment. Control
MCF10Acellswereslightlyinhibitedincellgrowthwith 15 mMan d
20 mM of SFN after 6 days of treatment, indicating that the 15 mM
and higher SFN doses might be toxic to the normal breast cells. The
morphology of human breast cancer cells treated with SFN was also
changed as shown in Fig 1B. SFN-treatment clearly induced cell
death and inhibitedcellular proliferation inthesebreastcancercells,
whereas the equivalent SFN-doses were found to have very
negligible cellular effects on normal MCF10A breast cells. We have
alsoperformed the colonogenic assay and found that treatment with
SFN significantly reduces MCF-7 and MDA-MB-231 cell prolifer-
ation at doses of 10 mM SFN or higher, while very slight but non-
significant cellular proliferation inhibition was found in control
MCF10A cells (Fig 1C). These results indicate that SFN, at dosages
of 10 mM or less, selectively inhibit breast cancer cells.
SFN inhibits hTERT expression in breast cancer cells
It is well known that most of the cancer cells express elevated
levels of telomerase, which allows these cells to survive, proliferate
and bypass cellular senescence. Thus, it is important to assess the
telomerase activity and hTERT, the key catalytic component of
telomerase, alterations in these breast cancer cells with SFN-
treatment. To investigate the effect of SFN on hTERT expression
and telomerase activity, we performed real-time PCR and
telomerase activity assay by ELISA, respectively. As shown in
Fig. 2A, SFN at 5 mM or higher greatly inhibits hTERT expression
in a dose- and time-dependent manner. The effect at 10 mM SFN
is significant by 6 days in both MCF-7 (P,0.05) and MDA-MB-
231 (P,0.05) cells. This is consistent with previous findings that
inhibition of hTERT by chemopreventive compounds is one of the
important contributing factors in cancer chemoprevention [31,34–
35]. We also assessed the effect of SFN on telomerase activity and
observed a dose- and time-dependent inhibition in breast cancer
cells. As illustrated in Fig. 2B, we found that SFN-treatment of
breast cancer cells significantly reduced telomerase activity by 1.5-
and 1.0-fold in MCF-7 (P,0.05) and MDA-MB-231 (P,0.05)
cells, respectively. Control MCF10A cells had low level of
telomerase activity (Fig. 2C) compared to breast cancer MCF-7
and MDA-MB-231 cells (Fig. 2A&2B). Treatment with SFN had
very negligible telomerase inhibitory activity in normal MCF10A
cells compared to untreated control cells. These results indicated
that SFN acts on hTERT and leads to its down-regulation
specifically on breast cancer cells, which may play a critical role in
inhibition of cancer cell proliferation and survival.
Alteration of methylation status leads to binding of CTCF
to exon 1 of the hTERT gene
It is well known that DNA methylation plays an important
role in gene expression and regulation, especially hTERT
expression [19–20,31]. Further, to explore the molecular
mechanism of SFN-induced repression of hTERT expression,
we examined the methylation status of the hTERT regulatory
region (from 2202 to +106) in MCF-7 and MDA-MB-231 cells.
A total of 37 CpG sites containing many overlapping
transcription factor binding sitesw e r ea n a l y z e df o rs i t e - s p e c i f i c
methylation status using bisulfite methylation sequencing anal-
ysis. However, there were only very slight methylation changes
found in the core hTERT promoter region (2202 to 278) with
SFN-treatment in both MCF-7 and MDA-MB-231 cells as well
as control MCF10A cells (Fig 3B, C, D). In control (non-SFN-
treated) MCF-7 and MDA-MB-231 cells, a very intense
hypermethylation was found at the translation start site and
CTCF binding region on the hTERT promoter, whereas, a very
low level of methylation was observed in these regions in
MCF10A cells. Conversely, the translation start site and CTCF
binding site in the hTERT regulatory region was considerably
demethylated with 5 mM SFN (50%) and 10 mM SFN (61%)
treatment in MCF-7 cells (Fig 3B). Consistent with MCF-7 cells,
MDA-MB-231 cells also underwent dramatic demethylation in
these regions of the hTERT 59-regulatory region with SFN-
treatment in a dose-dependent manner. However, SFN treat-
ment with MCF10A had a very negligible demethylation effect
on the CTCF binding region of the hTERT regulatory region
from 25% (SFN-untreated) to 14% (10 mM SFN-treated). It is
known that CTCF binds to exon 1 of the hTERT gene and this
methylation-sensitive transcription factor binding to hTERT
drastically reduces hTERT expression [22]. CTCF binds to its
unmethylated recognition sequence in the hTERT exon 1,
whereas methylation of this site interferes with CTCF binding
and reverses the gene expression [22]. Therefore, we asked
whether SFN-mediated demethylation of the CTCF binding site
enhances CTCF binding to the hTERT promoter in MCF-7 and
MDA-MB-231 cells. Using quantitative-ChIP (q-ChIP) analyses,
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the CTCF binding to the hTERT exon 1 binding site both in
MCF-7 and MDA-MB-231 (Fig 4A, left panel) cells. We also
found elevated binding of CTCF to the hTERT promoter in
SFN-untreated MCF10A cells and treatment with SFN slightly
elevated the CTCF binding to the hTERT promoter. Therefore,
SFN-mediated demethylation of CpGs of the CTCF binding
sites may facilitate the binding of CTCF to the hTERT gene
regulatory region to allow for CTCF-mediated down-regulation
of hTERT expression in MCF-7 and MDA-MB-231 cells.
Sulforaphane induced chromatin modification of the
hTERT promoter
Previous studies have shown that hTERT is epigenetically
regulated and its expression is often modulated by epigenetic
processes [15–16,35]. It is well established that SFN has HDAC
inhibitory activity, which is one of the contributing factors for
histone acetylation [9–10]. Since methylation changes were found
at CpG sites of the CTCF region in the hTERT regulatory region,
we sought to determine changes in histone modification of the
hTERT regulatory region by SFN-treatment in MCF-7, MDA-
Figure 1. SFN inhibits proliferation of breast cancer cells but has negligible effect on control MCF10A cells up to 10 mM SFN. A) Breast
cancerMCF-7(leftpanel)andMDA-MB-231(middlepanel)cellsaswellascontrolMCF10Acells(rightpanel) weretreatedwithSFN(0–20 mM)for3,6 and
9 days.Growthcurvekineticswasobtainedbycountingthetotalnumberofviablecellsatthe indicatedtimeintervalsusingtrypanblue staining. Results
were obtained from three independent experiments, mean 6 SD. B) Morphological changes with SFN treatment on MCF-7 (left panel), MDA-MB-231
(middle panel) and MCF10A (right panel) cells. The white floating cells are indicative of apoptotic/dead cells. View, X100. C) Treatment with SFN (0–
20 mM)inhibits the proliferationpotential ofhumanbreast cancerMCF-7(leftpanel)andMDA-MB-231(middle panel)cellsina dose-dependentmanner.
Control MCF10A cells (right panel) did not show a significant inhibition of colony forming potential at lower doses of SFN. Proliferation of cells was
assayed by the colonogenic assay. Colonies were stained using trypan blue and the total number counted at the end of the 15-day period protocol. The
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resulted in enrichment of transcriptionally active chromatin
markers, acetylated histone H3 (ac-H3) and H3 at lysine 9 (ac-
H3K9) in both MCF-7 and MDA-MB-231 cells but not in
MCF10A cells (Fig 4B). Acetylated histone H4 (ac-H4) were found
to be elevated in all three breast cells, although MDA-MB-231
cells were found to have more enrichment of ac-H4 (fig 4A, right
panel). We also found decreases in the methylation status of
histone inactive markers such as trimethyl-H3 lysine 27 (tri-me-
H3K27) and trimethyl-H3 lysine 9 (tri-me-H3K9) in MCF-7 and
MDA-MB-231 cells with SFN-treatment (Fig 4C). SFN-treatment
with MCF10A had negligible changes in tri-me-H3K9 and slight
increases in tri-me-H3K27 levels. These changes of histone
acetylation allow chromatin open structure to recruit repressor
binding to the hTERT 59-regulatory region [15,19]. Furthermore,
continuous SFN-treatment might also inhibit HDACs expression
and their activity, due to the possible direct interaction of SFN
with the HDACs active site, thereby inducing histone acetylation
[36]. Active and inactive chromation modulations can control the
antagonistic binding of MAD1 and c-MYC to the two E-boxes of
the hTERT promoter, which are a major repressors and activators,
respectively, of hTERT [16,37]. Indeed, we found that the MAD1
repressor of hTERT is increased in its binding in response to SFN
and the c-MYC activator is decreased in its binding to the hTERT
promoter in MCF-7, MDA-MB-231 and MCF10A cells (Fig 4D).
These results in combination with the results for CTCF binding
(Fig 4A, left panel) provide key findings for the mechanisms of
SFN-mediated hTERT inhibition in both MCF-7 and MDA-MB-
231 breast cancer cells.
Sulforaphane altered epigenetic enzymes expression and
their activity
To further understand the epigenetic modulations that occurred
in the hTERT 59-control region, we assessed epigenetic-related
enzymatic expression and activity of DNMTs (DNMT1,
DNMT3a and DNMT3b), HDACs and HATs in MCF-7 (Fig 5,
left panel), MDA-MB-231 (Fig 5, middle panel) and non-
tumorigenic MCF10A cells (Fig 5, right panel), with SFN
treatment. To our surprise, we discovered that SFN can
considerably inhibit DNMT1 and 3a expression in a dose-
dependent manner in human breast cancer cells and the inhibition
was less in normal MCF10A cells. However, SFN has little if any
effect on DNMT3b in MCF-7, MDA-MB-231 and MCF10A cells.
As indicated in Fig 5A (graphical representation), 10 mM SFN in 6
days inhibited DNMT1 and DNMT3a expression in MCF-7 cells
by 62% and 81%, respectively. In MDA-MB-231 cells, 10 mM
SFN in 6 days inhibited DNMT1 and DNMT3a expression by
48% and 78%, respectively. The SFN-mediated inhibition of
DNMTs expression could be an important contributing factor in
facilitating demethylation at CTCF binding region on hTERT
promoter observed in this study. Further, we also found that the
hTERT repressor transcription factor, CTCF, is also increased in
Figure 2. SFN inhibits telomerase in breast cancer cells. SFN inhibits hTERT mRNA expression in MCF-7 (left panel) and MDA-MB-231 (middle
panel) human breast cancer cells but not in control MCF10A cells (right panel). A) Relative mRNA levels of hTERT in control (nontreated) as well as SFN
(2.5–10 mM) treated cells were quantified at 6 and 9 days using real-time PCR. Data are in triplicates from three independent experiments and were
normalized to GAPDH. The values were plotted against control as relative fold induction 6 SD,
*P,0.05 is considered as significant. B) SFN inhibits
telomerase activity in MCF-7 (left panel) and MDA-MB-231 (middle panel) human breast cancer cells but has negligible effect on control MCF10A cells
(right panel). Telomerase activity was assayed with control (nontreated) as well as SFN-treated (2.5–10 mM) cells for 6 days. Telomerase activity was





PLoS ONE | www.plosone.org 6 July 2010 | Volume 5 | Issue 7 | e11457Figure 3. SFN induced methylation alteration of the hTERT promoter regions in normal and breast cancer cells. A) A generalized outline
of the hTERT gene is shown with all 16 exons (15 introns) and other transcription factor binding sites. The hTERT promoter region contains distal E-
box (binding site c-Myc/Mad1), 2247 to 2237, and the five SP1 sites, 2187 to 2179, 2165 to 2160, 2133 to 2125, 2113 to 2101, and 284 to 279.
E2F binding sites are located at 2313 to 2308, 2174 to 2169 and 267 to 262. The proximal E-box is located at 234 to 229 from the translational
starting site labeled as +1. The positions of exons 1 to 16 are shown in the hTERT gene and their intron nucleotide (nt) positions are shown at the end
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expression in a dose-dependent manner with SFN treatment. It is
known that SFN is an HDAC inhibitor; similarly, we have also
found that SFN treatment significantly inhibited HDAC activity in
these breast cancer cells. However, we did not find any
considerable alterations in HAT activity with SFN treatment in
these breast cells (Fig 5C). These results suggest that SFN-mediated
HDAC activity allows chromatin remodeling for access of various
transcription factors to the hTERT promoter; and DNMTs as well
as RBP2-mediated demethylation facilitates repressors such as
CTCF and MAD1 to bind to the hTERT gene control region,
collectively contributing to hTERT repression in these breast
cancer cells.
Knockdown of CTCF restores hTERT expression and
decreases apoptosis in SFN-treated breast cancer cells
To further analyze the SFN-mediated repressive effect of
hTERT expression by CTCF binding to the hTERT control
region, we transiently transfected CTCF siRNA into the MCF-7
and MDA-MB-231 cells. Transfection of CTCF siRNA for 3 and
6 days considerably knocked down CTCF expression in both
MCF-7 (Fig 6A, left panel) and MDA-MB-231 (Fig 6A, right panel)
cells. In contrast with CTCF down-regulation, we found an
elevated expression of hTERT mRNA in both human breast
cancer cells in response to CTCF siRNA treatment (Fig 6B). We
also found that partial knockdown of CTCF can partially reverse
the inhibitory effect of SFN at 10 mM after 6 days of culture. The
partial inhibition of hTERT expression with SFN-treated CTCF
knockdown cells might be due to the binding of other transcription
repressors such as MAD1, on the hTERT promoter (Fig 4A).
However, from our results it is evident that knockdown of CTCF
can reverse the inhibitory effect of SFN on hTERT expression.
Further, we also analyzed the role of CTCF-regulated hTERT
expression on SFN-induced apoptosis in breast cancer cells
(Fig 6C). It was found that breast cancer cells treated with
10 mM SFN for 6 days significantly induced cellular apoptosis in
both MCF-7 (P,0.05) and MDA-MB-231 cells (P,0.05).
Conversely, SFN-induced cellular apoptosis was significantly
reduced with CTCF knockdown with the restoration of hTERT
expression in MCF-7 and MDA-MB-231 cells (Fig 6B, C). These
results clearly indicate that CTCF is an important transcription
factor required for SFN-mediated cellular apoptosis in human
breast cancer cells. Therefore, SFN-induced cellular apoptosis is
mediated, at least in part, by epigenetic modulation of CTCF
binding to the hTERT regulatory exonic region and regulation of
hTERT expression in human breast cancer cells is highly
responsive to SFN treatments.
Discussion
Botanical agents, particularly those that can be administered
as dietary supplements, offer promising new options for the
development of more effective chemopreventive and chemother-
apeutic strategies. Sulforaphane (SFN) represents one such dietary
botanical agent that has been indicated to have HDAC inhibitory
activity [9–12]. Some HDAC inhibitors have been shown to have
remarkable anti-tumor activity and are presently under clinical
investigation [38–39]. Previous studies have demonstrated that
exposure to HDAC inhibitors such as TSA can induce apoptosis
and cell cycle arrest in various cancer cell lines [6,26–27]. SFN has
also been shown to have anti-proliferative and pro-apoptotic
effects in many cancer cells, including breast cancer [3,5–6]. In
our present study, lower doses of SFN selectively inhibited cellular
growth of breast cancer cells and had negligible effects on control
breast cells. This is in accordance with previous findings that SFN
induces cell type-specific apoptosis in breast cancer cells with
activation of Bax/Bcl-2 and caspases [3]. However, the molecular
triggers for induction or inhibitions of various genes specific to
these pathways have not yet been fully elucidated. SFN-mediated
HDAC inhibition activity causes a wide range of epigenetic
alterations in many genes which are actively involved in malignant
progression of cancer cells. HDAC inhibitors such as TSA induce
histone hyperacetylation at the hTERT promoter and transactivate
hTERT expression in telomerase-negative cells [24]. TSA-induced
histone acetylation facilitates an open chromatin structure and
allows for repressor protein binding to the hTERT promoter,
which reduces hTERT transcription and leads to cellular apoptosis
[19,27].
In an attempt to identify potential epigenetic changes which
mediate the effect of SFN on hTERT expression, we assessed the
methylation status of CpG islands embedded in the hTERT control
region (2202 to +106) in breast cancer as well as control non-
tumorigenic MCF10A cells. In accordance with previous studies,
the core promoter was partially methylated and an increased
methylation pattern was identified at the first exonic region of the
hTERT promoter in breast cancer cells [19–20]. Surprisingly,
much less CpG methylation was found in the core promoter as
well as the exon 1 region in MCF10A cells. SFN-induced dose-
dependent demethylation of the exon 1 region which is located
downstream of the transcriptional start site of the hTERT
promoter might allow methylation-sensitive transcription factors
such as CTCF to bind to the hTERT control region. CTCF is
known to be an hTERT repressor and is associated with exon 1 of
hTERT when the binding site is unmethylated [21–22]. Further,
our ChIP analysis confirmed that SFN-induced demethylation at
the first exon of the hTERT promoter results in increased binding
of CTCF to the hTERT control region to allow for CTCF-
mediated repression of hTERT transcription. Furthermore, unlike
most human gene promoters in which CpG island demethylation
leads to gene activation, hTERT control region demethylation is
associated with transcriptional repression of hTERT expression
[40].
Chromatin remodeling resulting from reversible acetylation of
histones has been suggested to be a critical component of
transcriptional regulation of hTERT expression [41]. In general,
acetylation of histones leads to chromatin remodeling and
facilitates transcriptional activation, whereas deacetylation causes
transcriptional silencing. Histone acetylation and decetylation-
modulated chromatin structure can be accessed with a number of
transcription factors, including c-MYC and MAD1, which
of the each exon. CpG density and various transcription factor binding sites in the hTERT promoter region are shown with the magnified dotted
arrow. B) Methylation status of the hTERT promoter and 59 exon region (2202 to +106 nucleotide) of breast cancer MCF-7 cells treated with SFN (0, 5,
10 mM) for 6 days. C) Methylation status of hTERT promoter and 59 exon region (2202 to +106 nucleotide) of breast cancer MDA-MB-231 cells treated
with SFN (0, 5, 10 mM) for 6 days. D) Methylation status of hTERT promoter and 59 exon region (2202 to +106 nucleotide) of breast cancer MCF10A
cells treated with SFN (0, 5, 10 mM) for 6 days. After PCR amplification of bisulfite-modified DNA and cloning into pGEM-T vector, several clones for
each treatment were analyzed by DNA sequencing. Each square represents one CpG site. Filled squares: methylated; open squares: unmethylated.
The number of methylated squares was counted from the total number of squares at the CTCF binding region for analyzing percent methylation at
the CTCF binding region in the hTERT regulatory region.
doi:10.1371/journal.pone.0011457.g003
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respectively [41]. In accordance with earlier findings, we have
also found that SFN treatment significantly inhibited HDAC
activity in breast cancer cells; however, we did not find any
significant alterations in HAT activity. In contrast, epigallocate-
chin-3-gallate (EGCG), one of the major constituents of green tea
polyphenols, specifically inhibits HAT but not HDAC activity
[42]. The SFN-mediated HDAC inhibition might be due to the
Figure 4. SFN induced histone modification changes of the hTERT promoter in normal and breast cancer cells. Breast cancer MCF-7 and
MDA-MB-231 as well as non-tumorigenic MCF10A cells were treated with the indicated concentrations of SFN for 6 days, and analyzed by ChIP-qPCR
assays using chromatin markers including acetyl-H3 (B, left panel) acetyl-H3K9 (B, right panel), acetyl-H4 (A, right panel), trimethyl-H3K27 (C, left
panel) and trimethyl-H3K9 (C, right panel) as well as CTCF (A, left panel), MAD1 (D, left panel) and c-MYC (D, right panel) in the promoter region of
hTERT. No antibody controls were also assessed to verify the ChIP efficiency. qPCR primers and conditions were used as described in Materials and
Methods. The x axis represents the SFN doses inmM, and the y axis represents the relative enrichment of individual binding factors, the percentage of
immunoprecipitates compared with the corresponding input samples (defined as 100). The experiment was repeated three times with triplicate in
real-time PCR and each point indicates the mean 6 SD.
doi:10.1371/journal.pone.0011457.g004
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We found that SFN-induced chromatin alterations facilitate a
dose-dependent enrichment of transcriptional active chromatin
markers such as acetylated histone H3, H3K9 and acetyl-H4 in
human breast cancer cells, whereas chromatin inactive markers
such as trimethyl-H3K27 and trimethyl-H3K9 were decreased.
Therefore, we provide several lines of evidence that SFN-mediated
hyperacetylation facilitates the binding of various hTERT
Figure 5. SFN altered epigenetic enzymes expression and their activity in normal and breast cancer cells. A) Effect of SFN on DNMTs,
CTCF and RBP2 expression in human breast cancer MCF-7 (left panel) and MDA-MB-231 (middle panel) as well as non-tumorigenic MCF10A (right
panel) cells. Cell lysates were prepared at 6 days after SFN-treatment at the indicated doses followed by western blotting to analyze DNMTs (DNMT1,
DNMT3a and DNMT3b), CTCF and RBP2 expression. Actin was used as an equal loading control. Graphical representations are indicative of relative
band intensity of DNMTs expression in MCF-7 (left panel), MDA-MB-231 (middle panel) and MCF10A (right panel) cells, normalized with b-actin.
Values are mean of three independent experiments, band intensity 6 SD. B) SFN inhibits HDAC activity. Breast cancer MCF-7 (left panel), MDA-MB-231
(middle panel) and control MCF10A (right panel) cells were treated with the indicated concentration of SFN for 6 days. Nuclear extracts were
prepared and 20 mg of protein was used to estimate HDAC activity using the HDAC colorimetric assay kit. Values are representative of three
independent experiments and represented as percent control 6 SD;
*P,0.05. C) SFN treatment has no effect on the HAT activity. Breast cancer MCF-7
(left panel), MDA-MB-231 (middle panel) and control MCF10A (right panel) cells were treated with the indicated concentrations of SFN for 6 days.
Nuclear extracts were prepared and 20 mg of protein was used to estimate HAT activity. Values are representative of three independent experiments




PLoS ONE | www.plosone.org 10 July 2010 | Volume 5 | Issue 7 | e11457Figure 6. Knockdown of CTCF restores hTERT expression and decreases apoptosis in SFN-treated breast cancer cells. A) Breast cancer
MCF-7 (left panel) and MDA-MB-231 (right panel) cells were subjected to treatments with 9 nM of CTCF siRNA or control siRNA fragments. Effects of
siRNA interference with CTCF gene expression was assayed after 6 days using specific antibodies to CTCF and b-actin by western blot analysis. Data
shown are representative of the three separate experiments. B) CTCF and control siRNA transfected cells were treated with 10 mM SFN for 6 days and
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control region in breast cancer cells. Our results also suggest that
SFN-induced MAD1 binding might recruit RBP2, a histone
demethylase, which is responsible for the inhibition of chromatin
inactive markers, thereby contributing to a stable repression of
hTERT expression [23].
Another important discovery of this study is that SFN reduced
DNMTs (DNMT1 and DNMT3a) activity in human breast
cancer cells. DNMTs catalyze the methylation of genomic DNA.
Of these, DNMT1 acts as a maintenance methyltransferase,
whereas DNMT3a and DNMT3b exhibit de novo activity. In
addition, DNMT1 induces hypermethylation of tumor suppressor
genes to epigenetically repress their activation in tumorigenesis
processes in many cancers including colon cancer [43]. Previously,
we also have shown that genistein and EGCG result in down-
regulation of the DNMTs which is directly associated with
repression of hTERT expression through hTERT promoter
demethylation in breast cancer cells [31,44]. Numerous studies
have also reported that DNA methylation plays important roles in
hTERT transcriptional regulation [37,44]. Together, our results
suggest that SFN-induced down-regulation of DNMTs expression
is not only involved in the demethylation processes of the hTERT
control region in the process of anti-carcinogenesis, but also
enhances binding of methylation-sensitive transcription factors
such as CTCF to the hTERT regulatory region. Studies have
shown that demethylating agents such as 5-azacytidine lead to a
strong demethylation of the hTERT 59-regulatory region, reacti-
vation of CTCF binding and down-regulation of hTERT [21].
Convincingly, we found an inverse relationship between CTCF
binding to the hTERT promoter with hTERT mRNA transcription
in human breast cancer cells. In addition, CTCF siRNA
experiments clearly demonstrated that depletion of CTCF restores
the SFN-induced down-regulation of hTERT mRNA transcription
in these breast cancer cells. Furthermore, down-regulation of
hTERT expression facilitates the induction of cellular apoptosis in
human breast cancer cells. This is consistent with previous findings
that inhibition of hTERT by chemopreventive compounds is
associated, at least in part, with the induction of cellular apoptosis
[31,34–35,44]. Taken together, it is apparent that DNMTs-
induced promoter demethylation and CTCF binding to the
hTERT regulatory region are closely linked to the control of
hTERT expression by SFN in breast cancer cells.
In the present study, we demonstrated not only SFN-induced
down-regulation of telomerase in breast cancer cells but also
explored possible epigenetic mechanisms such as demethylation at
the first exon of hTERT and CTCF binding in relation to hTERT
repression. It is important to point out that hTERT gene control is
unique and the proposed mode of action is not the only way SFN
inhibits cancer cell growth. The maximum concentrations used in
this study were 10 mM and found to be the ideal dose for in vivo
inhibition of HDAC activity in the colonic mucosa [38]. For
humans to obtain concentrations of SFN similar to those we have
used, one would have to consume about 1 cup (106 g) of broccoli
sprouts per day based on in vivo studies which is well within
practical limits [10,38]. While this work is aimed at elucidating the
mechanism by which SFN down-regulates hTERT expression,
further in vivo confirmation is warranted. However, the SFN-
induced epigenetic alterations observed in this and other
investigations make it an attractive target for chemoprevention
in varying cancer cell types.
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